Suramin inhibits glioma cell proliferationin vitro and in the brain

摘要: Suramin is a novel anticancer agent that blocks the binding of growth factors, including basic fibroblast factor (bFGF), to their receptors. Prior studies showed human and experimental gliomas upregulate respond autocrine stimulation by bFGF, antiproliferative effects suramin were therefore studied on glioma cell turnoverin vitro in brain. inhibited rat (C6,9L) (U-118, U-138, A-172, T98G) lines dose-dependent manner. significantly reduced bromodeoxyuridine (BUdR) labeling index cultured cells at 250 µg/ml, P < 0.0001. DNA flow cytometry revealed significant decrease percentage suramin-treated S-phase, 0.01. Using intracerebral C6 modelin vivo, suramin, 10–60 mg/kg, i.p., produced reduction BUdR both endothelial subpopulations. Suramin, 200 mg/kg i.V., however, led intratumoral hemorrhages survival. Electron microscopy membranous inclusion bodies cytoplasm cells, an indication excess glycosaminoglycans. Moreover, 46% within tumor treated with 60 developed membrane blebs. clinically relevant doses, inhibits cytokinetics. The risk hemorrhage, possibly related injury or accumulation anticoagulant glycosaminoglycans, constitutes major side effect caution should be exercised consideration clinical application for tumors.